key

pocket_crf_0.45

named	VBN	, VBD VBN NN IN	O
president	NN	VBD VBN NN IN NNP	B
of	IN	VBN NN IN NNP NNP	O
Manville	NNP	NN IN NNP NNP NNP	B
Forest	NNP	IN NNP NNP NNP NNP	I
Products	NNP	NNP NNP NNP NNP ,	I
Corp.	NNP	NNP NNP NNP , DT	I
,	,	NNP NNP , DT NNP	O
a	DT	NNP , DT NNP NN	B
Manville	NNP	, DT NNP NN ,	I
unit	NN	DT NNP NN , CC	I
,	,	NNP NN , CC JJ	O
and	CC	NN , CC JJ NN	O
senior	JJ	, CC JJ NN NN	B
vice	NN	CC JJ NN NN IN	I
president	NN	JJ NN NN IN NNP	I
of	IN	NN NN IN NNP NNP	O
Manville	NNP	NN IN NNP NNP .	B
Corp	NNP	IN NNP NNP .	I
.	.	NNP NNP .	O

Mr.	NNP	NNP NNP VBZ	B
Johnson	NNP	NNP NNP VBZ NNP	I
succeeds	VBZ	NNP NNP VBZ NNP NNP	O
Harry	NNP	NNP VBZ NNP NNP NNP	B
W.	NNP	VBZ NNP NNP NNP ,	I
Sherman	NNP	NNP NNP NNP , WP	I
,	,	NNP NNP , WP VBD	O
who	WP	NNP , WP VBD TO	B
resigned	VBD	, WP VBD TO VB	O
to	TO	WP VBD TO VB JJ	O
pursue	VB	VBD TO VB JJ NNS	O
other	JJ	TO VB JJ NNS ,	B
interests	NNS	VB JJ NNS , IN	I
,	,	JJ NNS , IN DT	O
in	IN	NNS , IN DT NNS	O
both	DT	, IN DT NNS .	B
positions	NNS	IN DT NNS .	I
.	.	DT NNS .	O

Manville	NNP	NNP VBZ DT	B
is	VBZ	NNP VBZ DT NN	O
a	DT	NNP VBZ DT NN CC	B
building	NN	VBZ DT NN CC NN	I
and	CC	DT NN CC NN NNS	I
forest	NN	NN CC NN NNS VBP	I
products	NNS	CC NN NNS VBP .	I
concern	VBP	NN NNS VBP .	I
.	.	NNS VBP .	O

US	PRP	PRP NNP NNP	B
Facilities	NNP	PRP NNP NNP VBD	I
Corp.	NNP	PRP NNP NNP VBD NNP	I
said	VBD	NNP NNP VBD NNP NNP	O
Robert	NNP	NNP VBD NNP NNP NNP	B
J.	NNP	VBD NNP NNP NNP VBD	I
Percival	NNP	NNP NNP NNP VBD TO	I
agreed	VBD	NNP NNP VBD TO VB	O
to	TO	NNP VBD TO VB RB	O
step	VB	VBD TO VB RB IN	O
down	RB	TO VB RB IN NN	O
as	IN	VB RB IN NN NN	O
vice	NN	RB IN NN NN IN	B
chairman	NN	IN NN NN IN DT	I
of	IN	NN NN IN DT NN	O
the	DT	NN IN DT NN VBG	B
insurance	NN	IN DT NN VBG NN	I
holding	VBG	DT NN VBG NN .	I
company	NN	NN VBG NN .	I
.	.	VBG NN .	O

``	``	`` EX VBD	O
There	EX	`` EX VBD DT	B
was	VBD	`` EX VBD DT NN	O
a	DT	EX VBD DT NN IN	B
difference	NN	VBD DT NN IN NN	I
of	IN	DT NN IN NN IN	O
opinion	NN	NN IN NN IN TO	B
as	IN	IN NN IN TO DT	O
to	TO	NN IN TO DT NN	O
the	DT	IN TO DT NN NN	B
future	NN	TO DT NN NN IN	I
direction	NN	DT NN NN IN DT	I
of	IN	NN NN IN DT NN	O
the	DT	NN IN DT NN ,	B
company	NN	IN DT NN , ''	I
,	,	DT NN , '' DT	O
''	''	NN , '' DT NN	O
a	DT	, '' DT NN VBD	B
spokeswoman	NN	'' DT NN VBD .	I
said	VBD	DT NN VBD .	O
.	.	NN VBD .	O

Mr.	NNP	NNP NNP VBD	B
Percival	NNP	NNP NNP VBD TO	I
declined	VBD	NNP NNP VBD TO VB	O
to	TO	NNP VBD TO VB .	O
comment	VB	VBD TO VB .	O
.	.	TO VB .	O

In	IN	IN DT NN	O
a	DT	IN DT NN ,	B
statement	NN	IN DT NN , PRP	I
,	,	DT NN , PRP NNPS	O
US	PRP	NN , PRP NNPS VBD	B
Facilities	NNPS	, PRP NNPS VBD NNP	I
said	VBD	PRP NNPS VBD NNP NNP	O
Mr.	NNP	NNPS VBD NNP NNP POS	B
Percival	NNP	VBD NNP NNP POS NN	I
's	POS	NNP NNP POS NN NN	B
employment	NN	NNP POS NN NN VBZ	I
contract	NN	POS NN NN VBZ IN	I
calls	VBZ	NN NN VBZ IN PRP	O
for	IN	NN VBZ IN PRP TO	O
him	PRP	VBZ IN PRP TO VB	B
to	TO	IN PRP TO VB IN	O
act	VB	PRP TO VB IN DT	O
as	IN	TO VB IN DT NN	O
a	DT	VB IN DT NN TO	B
consultant	NN	IN DT NN TO DT	I
to	TO	DT NN TO DT NN	O
the	DT	NN TO DT NN IN	B
company	NN	TO DT NN IN CD	I
for	IN	DT NN IN CD NNS	O
two	CD	NN IN CD NNS .	B
years	NNS	IN CD NNS .	I
.	.	CD NNS .	O

He	PRP	PRP MD RB	B
will	MD	PRP MD RB VB	O
also	RB	PRP MD RB VB DT	O
remain	VB	MD RB VB DT NN	O
a	DT	RB VB DT NN ,	B
director	NN	VB DT NN , PRP	I
,	,	DT NN , PRP NNPS	O
US	PRP	NN , PRP NNPS VBD	B
Facilities	NNPS	, PRP NNPS VBD ,	I
said	VBD	PRP NNPS VBD , CC	O
,	,	NNPS VBD , CC MD	O
but	CC	VBD , CC MD RB	O
wo	MD	, CC MD RB VB	O
n't	RB	CC MD RB VB IN	O
serve	VB	MD RB VB IN DT	O
on	IN	RB VB IN DT NN	O
any	DT	VB IN DT NN NNS	B
board	NN	IN DT NN NNS .	I
committees	NNS	DT NN NNS .	I
.	.	NN NNS .	O

Mr.	NNP	NNP NNP MD	B
Percival	NNP	NNP NNP MD VB	I
will	MD	NNP NNP MD VB VBN	O
be	VB	NNP MD VB VBN IN	O
succeeded	VBN	MD VB VBN IN DT	O
on	IN	VB VBN IN DT JJ	O
an	DT	VBN IN DT JJ NN	B
interim	JJ	IN DT JJ NN IN	I
basis	NN	DT JJ NN IN NNP	I
by	IN	JJ NN IN NNP NNP	O
George	NNP	NN IN NNP NNP ,	B
Kadonada	NNP	IN NNP NNP , PRP	I
,	,	NNP NNP , PRP NNPS	O
US	PRP	NNP , PRP NNPS NN	B
Facilities	NNPS	, PRP NNPS NN CC	I
chairman	NN	PRP NNPS NN CC NN	I
and	CC	NNPS NN CC NN .	I
president	NN	NN CC NN .	I
.	.	CC NN .	O

In	IN	IN DT JJ	O
the	DT	IN DT JJ NN	B
same	JJ	IN DT JJ NN ,	I
statement	NN	DT JJ NN , PRP	I
,	,	JJ NN , PRP NNPS	O
US	PRP	NN , PRP NNPS RB	B
Facilities	NNPS	, PRP NNPS RB VBD	I
also	RB	PRP NNPS RB VBD PRP	O
said	VBD	NNPS RB VBD PRP VBD	O
it	PRP	RB VBD PRP VBD VBN	B
had	VBD	VBD PRP VBD VBN RB	O
bought	VBN	PRP VBD VBN RB CD	O
back	RB	VBD VBN RB CD IN	O
112,000	CD	VBN RB CD IN PRP$	B
of	IN	RB CD IN PRP$ JJ	O
its	PRP$	CD IN PRP$ JJ NNS	B
common	JJ	IN PRP$ JJ NNS IN	I
shares	NNS	PRP$ JJ NNS IN DT	I
in	IN	JJ NNS IN DT JJ	O
a	DT	NNS IN DT JJ NN	B
private	JJ	IN DT JJ NN .	I
transaction	NN	DT JJ NN .	I
.	.	JJ NN .	O

Terms	NNS	NNS VBD RB	B
were	VBD	NNS VBD RB VBN	O
n't	RB	NNS VBD RB VBN .	O
disclosed	VBN	VBD RB VBN .	O
.	.	RB VBN .	O

The	DT	DT NN VBZ	B
buy-back	NN	DT NN VBZ IN	I
represents	VBZ	DT NN VBZ IN CD	O
about	IN	NN VBZ IN CD NN	B
3	CD	VBZ IN CD NN IN	I
%	NN	IN CD NN IN DT	I
of	IN	CD NN IN DT NN	O
the	DT	NN IN DT NN POS	B
company	NN	IN DT NN POS NNS	I
's	POS	DT NN POS NNS ,	B
shares	NNS	NN POS NNS , VBN	I
,	,	POS NNS , VBN IN	O
based	VBN	NNS , VBN IN DT	O
on	IN	, VBN IN DT CD	O
the	DT	VBN IN DT CD CD	B
3.7	CD	IN DT CD CD NNS	I
million	CD	DT CD CD NNS JJ	I
shares	NNS	CD CD NNS JJ IN	I
outstanding	JJ	CD NNS JJ IN IN	O
as	IN	NNS JJ IN IN NNP	O
of	IN	JJ IN IN NNP CD	O
Sept.	NNP	IN IN NNP CD .	B
30	CD	IN NNP CD .	I
.	.	NNP CD .	O

In	IN	IN JJ JJ	O
national	JJ	IN JJ JJ NN	B
over-the-counter	JJ	IN JJ JJ NN NN	I
trading	NN	JJ JJ NN NN ,	I
yesterday	NN	JJ NN NN , PRP	B
,	,	NN NN , PRP NNPS	O
US	PRP	NN , PRP NNPS VBD	B
Facilities	NNPS	, PRP NNPS VBD IN	I
closed	VBD	PRP NNPS VBD IN $	O
at	IN	NNPS VBD IN $ CD	O
$	$	VBD IN $ CD ,	B
3.625	CD	IN $ CD , JJ	I
,	,	$ CD , JJ .	O
unchanged	JJ	CD , JJ .	O
.	.	, JJ .	O

Three	CD	CD VBG NN	B
leading	VBG	CD VBG NN NNS	I
drug	NN	CD VBG NN NNS VBD	I
companies	NNS	VBG NN NNS VBD JJ	I
reported	VBD	NN NNS VBD JJ JJ	O
robust	JJ	NNS VBD JJ JJ NNS	B
third-quarter	JJ	VBD JJ JJ NNS ,	I
earnings	NNS	JJ JJ NNS , VBN	I
,	,	JJ NNS , VBN IN	O
bolstered	VBN	NNS , VBN IN JJ	O
by	IN	, VBN IN JJ NNS	O
strong	JJ	VBN IN JJ NNS IN	B
sales	NNS	IN JJ NNS IN JJR	I
of	IN	JJ NNS IN JJR ,	O
newer	JJR	NNS IN JJR , JJ	B
,	,	IN JJR , JJ NNS	I
big-selling	JJ	JJR , JJ NNS NNS	I
prescriptions	NNS	, JJ NNS NNS WDT	I
drugs	NNS	JJ NNS NNS WDT VBP	I
that	WDT	NNS NNS WDT VBP JJ	B
provide	VBP	NNS WDT VBP JJ NN	O
hefty	JJ	WDT VBP JJ NN NNS	B
profit	NN	VBP JJ NN NNS .	I
margins	NNS	JJ NN NNS .	I
.	.	NN NNS .	O

Merck	NNP	NNP CC NNP	B
&	CC	NNP CC NNP VBD	I
Co.	NNP	NNP CC NNP VBD DT	I
reported	VBD	CC NNP VBD DT CD	O
a	DT	NNP VBD DT CD NN	B
25	CD	VBD DT CD NN NN	I
%	NN	DT CD NN NN IN	I
increase	NN	CD NN NN IN NNS	I
in	IN	NN NN IN NNS :	O
earnings	NNS	NN IN NNS : NNP	B
;	:	IN NNS : NNP NNP	O
Warner-Lambert	NNP	NNS : NNP NNP POS	B
Co.	NNP	: NNP NNP POS NN	I
's	POS	NNP NNP POS NN VBD	B
profit	NN	NNP POS NN VBD CD	I
rose	VBD	POS NN VBD CD NN	O
22	CD	NN VBD CD NN CC	B
%	NN	VBD CD NN CC NNP	I
and	CC	CD NN CC NNP NNP	O
Eli	NNP	NN CC NNP NNP CC	B
Lilly	NNP	CC NNP NNP CC NNP	I
&	CC	NNP NNP CC NNP POS	I
Co.	NNP	NNP CC NNP POS JJ	I
's	POS	CC NNP POS JJ NN	B
net	JJ	NNP POS JJ NN VBD	I
income	NN	POS JJ NN VBD CD	I
rose	VBD	JJ NN VBD CD NN	O
24	CD	NN VBD CD NN .	B
%	NN	VBD CD NN .	I
.	.	CD NN .	O

The	DT	DT NNS VBD	B
results	NNS	DT NNS VBD IN	I
were	VBD	DT NNS VBD IN NN	O
in	IN	NNS VBD IN NN IN	O
line	NN	VBD IN NN IN NNS	B
with	IN	IN NN IN NNS POS	O
analysts	NNS	NN IN NNS POS NNS	B
'	POS	IN NNS POS NNS .	B
expectations	NNS	NNS POS NNS .	I
.	.	POS NNS .	O

Merck	NNP	NNP CC NNP	B
&	CC	NNP CC NNP .	I
Co	NNP	NNP CC NNP .	I
.	.	CC NNP .	I

Merck	NNP	NNP , NNP	B
,	,	NNP , NNP ,	O
Rahway	NNP	NNP , NNP , NNP	B
,	,	, NNP , NNP ,	O
N.J.	NNP	NNP , NNP , VBD	B
,	,	, NNP , VBD TO	O
continued	VBD	NNP , VBD TO VB	O
to	TO	, VBD TO VB DT	O
lead	VB	VBD TO VB DT NN	O
the	DT	TO VB DT NN IN	B
industry	NN	VB DT NN IN DT	I
with	IN	DT NN IN DT JJ	O
a	DT	NN IN DT JJ NNS	B
strong	JJ	IN DT JJ NNS NN	I
sales	NNS	DT JJ NNS NN IN	I
performance	NN	JJ NNS NN IN DT	I
in	IN	NNS NN IN DT NN	O
the	DT	NN IN DT NN CC	B
human	NN	IN DT NN CC NN	I
and	CC	DT NN CC NN NNS	I
animal	NN	NN CC NN NNS VBP	I
health-products	NNS	CC NN NNS VBP .	I
segment	VBP	NN NNS VBP .	I
.	.	NNS VBP .	O

A	DT	DT JJR NNP	B
stronger	JJR	DT JJR NNP NN	I
U.S.	NNP	DT JJR NNP NN VBD	I
dollar	NN	JJR NNP NN VBD JJ	I
reduced	VBD	NNP NN VBD JJ CC	O
third-quarter	JJ	NN VBD JJ CC JJ	B
and	CC	VBD JJ CC JJ NNS	I
first-nine-month	JJ	JJ CC JJ NNS NN	I
sales	NNS	CC JJ NNS NN CD	I
growth	NN	JJ NNS NN CD NN	I
2	CD	NNS NN CD NN CC	B
%	NN	NN CD NN CC CD	I
and	CC	CD NN CC CD NN	I
3	CD	NN CC CD NN ,	I
%	NN	CC CD NN , RB	I
,	,	CD NN , RB .	O
respectively	RB	NN , RB .	O
.	.	, RB .	O

International	JJ	JJ NNS VBD	B
sales	NNS	JJ NNS VBD IN	I
accounted	VBD	JJ NNS VBD IN CD	O
for	IN	NNS VBD IN CD NN	O
47	CD	VBD IN CD NN IN	B
%	NN	IN CD NN IN JJ	I
of	IN	CD NN IN JJ NN	O
total	JJ	NN IN JJ NN NNS	B
company	NN	IN JJ NN NNS IN	I
sales	NNS	JJ NN NNS IN DT	I
for	IN	NN NNS IN DT CD	O
the	DT	NNS IN DT CD NNS	B
nine	CD	IN DT CD NNS ,	I
months	NNS	DT CD NNS , VBN	I
,	,	CD NNS , VBN IN	O
compared	VBN	NNS , VBN IN CD	O
with	IN	, VBN IN CD NN	O
50	CD	VBN IN CD NN DT	B
%	NN	IN CD NN DT NN	I
a	DT	CD NN DT NN RBR	B
year	NN	NN DT NN RBR .	I
earlier	RBR	DT NN RBR .	O
.	.	NN RBR .	O

Sales	NNS	NNS IN DT	B
for	IN	NNS IN DT NN	O
the	DT	NNS IN DT NN VBD	B
quarter	NN	IN DT NN VBD TO	I
rose	VBD	DT NN VBD TO $	O
to	TO	NN VBD TO $ CD	O
$	$	VBD TO $ CD CD	B
1.63	CD	TO $ CD CD IN	I
billion	CD	$ CD CD IN $	I
from	IN	CD CD IN $ CD	O
$	$	CD IN $ CD CD	B
1.47	CD	IN $ CD CD .	I
billion	CD	$ CD CD .	I
.	.	CD CD .	O

Mevacor	NNP	NNP , NNP	B
,	,	NNP , NNP POS	O
Merck	NNP	NNP , NNP POS JJ	B
's	POS	, NNP POS JJ JJ	B
new	JJ	NNP POS JJ JJ NN	I
cholesterol-lowering	JJ	POS JJ JJ NN ,	I
drug	NN	JJ JJ NN , VBD	I
,	,	JJ NN , VBD JJR	O
had	VBD	NN , VBD JJR NNS	O
higher	JJR	, VBD JJR NNS IN	B
vsales	NNS	VBD JJR NNS IN DT	I
than	IN	JJR NNS IN DT JJ	O
any	DT	NNS IN DT JJ NN	B
other	JJ	IN DT JJ NN NN	I
prescription	NN	DT JJ NN NN VBZ	I
medicine	NN	JJ NN NN VBZ RB	I
has	VBZ	NN NN VBZ RB VBN	O
ever	RB	NN VBZ RB VBN IN	O
achieved	VBN	VBZ RB VBN IN DT	O
in	IN	RB VBN IN DT NNP	O
the	DT	VBN IN DT NNP IN	B
U.S.	NNP	IN DT NNP IN DT	I
in	IN	DT NNP IN DT NN	O
the	DT	NNP IN DT NN VBG	B
year	NN	IN DT NN VBG NN	I
following	VBG	DT NN VBG NN ,	O
introduction	NN	NN VBG NN , DT	B
,	,	VBG NN , DT NN	O
the	DT	NN , DT NN VBD	B
company	NN	, DT NN VBD .	I
said	VBD	DT NN VBD .	O
.	.	NN VBD .	O

The	DT	DT NN VBD	B
drug	NN	DT NN VBD VBN	I
was	VBD	DT NN VBD VBN IN	O
introduced	VBN	NN VBD VBN IN NNP	O
in	IN	VBD VBN IN NNP NNP	O
West	NNP	VBN IN NNP NNP DT	B
Germany	NNP	IN NNP NNP DT NN	I
this	DT	NNP NNP DT NN .	B
year	NN	NNP DT NN .	I
.	.	DT NN .	O

Intense	JJ	JJ NN ,	B
competition	NN	JJ NN , RB	I
,	,	JJ NN , RB ,	O
however	RB	NN , RB , VBN	O
,	,	, RB , VBN TO	O
led	VBN	RB , VBN TO NN	O
to	TO	, VBN TO NN NNS	O
unit	NN	VBN TO NN NNS NNS	B
sales	NNS	TO NN NNS NNS IN	I
declines	NNS	NN NNS NNS IN DT	I
for	IN	NNS NNS IN DT NN	O
a	DT	NNS IN DT NN IN	B
group	NN	IN DT NN IN NNP	I
of	IN	DT NN IN NNP POS	O
Merck	NNP	NN IN NNP POS VBN	B
's	POS	IN NNP POS VBN NN	B
established	VBN	NNP POS VBN NN CC	I
human	NN	POS VBN NN CC NN	I
and	CC	VBN NN CC NN NNS	I
animal-health	NN	NN CC NN NNS ,	I
products	NNS	CC NN NNS , VBG	I
,	,	NN NNS , VBG NNP	O
including	VBG	NNS , VBG NNP CC	O
Aldomet	NNP	, VBG NNP CC NNP	B
and	CC	VBG NNP CC NNP .	I
Indocin	NNP	NNP CC NNP .	I
.	.	CC NNP .	O

In	IN	IN NNP NNP	O
New	NNP	IN NNP NNP NNP	B
York	NNP	IN NNP NNP NNP NNP	I
Stock	NNP	NNP NNP NNP NNP JJ	I
Exchange	NNP	NNP NNP NNP JJ NN	I
composite	JJ	NNP NNP JJ NN NN	I
trading	NN	NNP JJ NN NN ,	I
yesterday	NN	JJ NN NN , NNP	B
,	,	NN NN , NNP NNS	O
Merck	NNP	NN , NNP NNS VBD	B
shares	NNS	, NNP NNS VBD IN	I
closed	VBD	NNP NNS VBD IN $	O
at	IN	NNS VBD IN $ CD	O
$	$	VBD IN $ CD ,	B
75.25	CD	IN $ CD , IN	I
,	,	$ CD , IN CD	O
up	IN	CD , IN CD NNS	O
50	CD	, IN CD NNS .	B
cents	NNS	IN CD NNS .	I
.	.	CD NNS .	O

Warner-Lambert	NNP	NNP NNP .	B
Co	NNP	NNP NNP .	I
.	.	NNP NNP .	I

Warner-Lambert	NNP	NNP , NNP	B
,	,	NNP , NNP NNP	O
Morris	NNP	NNP , NNP NNP ,	B
Plains	NNP	, NNP NNP , NNP	I
,	,	NNP NNP , NNP ,	O
N.J.	NNP	NNP , NNP , VBD	B
,	,	, NNP , VBD NNS	O
reported	VBD	NNP , VBD NNS WDT	O
sales	NNS	, VBD NNS WDT VBD	B
that	WDT	VBD NNS WDT VBD DT	B
were	VBD	NNS WDT VBD DT NN	O
a	DT	WDT VBD DT NN IN	B
record	NN	VBD DT NN IN DT	I
for	IN	DT NN IN DT NN	O
any	DT	NN IN DT NN CC	B
quarter	NN	IN DT NN CC DT	I
and	CC	DT NN CC DT JJ	O
the	DT	NN CC DT JJ NN	B
eighth	JJ	CC DT JJ NN IN	I
quarter	NN	DT JJ NN IN DT	I
in	IN	JJ NN IN DT NN	O
a	DT	NN IN DT NN IN	B
row	NN	IN DT NN IN CD	I
of	IN	DT NN IN CD NN	O
20	CD	NN IN CD NN CC	B
%	NN	IN CD NN CC RBR	I
or	CC	CD NN CC RBR JJ	I
more	RBR	NN CC RBR JJ NNS	I
per-share	JJ	CC RBR JJ NNS NN	I
earnings	NNS	RBR JJ NNS NN .	I
growth	NN	JJ NNS NN .	I
.	.	NNS NN .	O